Marina Biotech, Inc. (MRNA) SEC Filing 8-K Material Event for the period ending Monday, October 1, 2018

Adhera Therapeutics, Inc.

CIK: 737207

View differences made from one to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..


Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Adhera Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

CIK: 737207
Form Type: 8-K Corporate News
Accession Number: 0001493152-18-014024
Submitted to the SEC: Wed Oct 03 2018 8:30:19 AM EST
Accepted by the SEC: Wed Oct 03 2018
Period: Monday, October 1, 2018
Industry: Pharmaceutical Preparations
  1. Ending Agreement
  2. Event for Officers
  3. Financial Exhibit
  4. New Agreement
  5. Other Events

External Resources:

Bookmark the Permalink: